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To investigate the influence of lidocaine on the energy
requirements for internal defibrillation, lidocaine (n =
8) or saline solution (n = 12) was administered by in-
travenous infusion to 20 pentobarbital-anesthetized dogs,
and the likelihood of successful defibrillation was ex-
amined at various shock energy levels before and after
treatment. After lidocaineadministration to a mean steady
state concentration of 5.6 ± 2.7 JLg/ml, the mean energy
required to achieve 50 and 90% success in defibrillation
(Eso and E90) increased by 61.1 ± 34.1% (mean ± SD,
p < 0.005) and 47.1 ± 28.6% (p < 0.005), respectively.
The steady state log lidocaine concentration correlated
positively with the observed increase in Eso (r = 0.887,
p < 0.01) over a concentration range from 1.95 to 9.8
JLg/mI. In a related experiment, lidocaine infusion was
The development of clinically applicable systems for inter-
nal defibrillation and the increa sed availability of defibril-
lation for cardiac arrest occurring in the community has
stimulated interest in the factors influencing cardiac defi-
brillation (1-6). The effect of clinical variables and thera-
peutic interventions on the amount of electrical energy re-
quired for successful defibrillation is also relevant to the use
of automatic internal defibrillators, which deliver an elec-
trical discharge of preset energy in response to ventricular
tachycardia or fibrillation (4,7) .
Patients at risk for ventricular fibrillation are often treated
with lidocaine, because this drug increases the threshold for
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administered to five dogs and then abruptly discontin-
ued. At energy levels achieving a mean 90.0 ± 10.0%
success in defibrillation before treatment, only 43.3 ±
23.4% success was achieved after 60 minutes of the lido-
caine infusion (p < 0.01) at a mean plasma concentration
of 8.4 ± 2.1 JLg/mI. The percent of successful defibril-
lations returned to baseline value (92.0 ± 18.0%, P <
0.01) after drug washout at a time when mean lidocaine
concentration had declined to 1.8 ± 0.5 JLg/ml.
Lidocaine causes a reversible , concentration-depen-
dent increase in the energy requirements for successful
defibrillation; recommendations to administer lidocaine
to patients with ventricular fibrillation resistant to de-
fibrillation may need to be reviewed.
(J Am Coil Cardiol 1986;8:327-32)
the induction of ventricular fibrillation (8,9) and is advo-
cated, among other indication s, for the treatment of ven-
tricular fibrillation resistant to electrical defibrillation (10,11).
Although lidocaine may effectively prevent primary ven-
tricular fibrillation in acute myocardial infarction (12), it
may also have deleterious effect s on the energy requirements
for defibrillation (13). It has been found to increase the
" defibrillation threshold" for transthoracic shocks (13) ;
however, the energy requirements for defibrillation using
internal electrodes have not been studied. It was recentl y
shown (14) that no single " threshold" energy value can be
defined below which defibrillation is uniformly unsucces sful
and above which it is uniformly successful; rather , the prob-
ability of successful defibrillation increases as the energy
delivered increases according to a sigmoid " dose-response
curve." In this study we explored the effect of lidocaine
on the relation between shock energy and the probability of
successful defibrillation using a system ofelectrodes suitable
for implantation.
Methods
Experimental protocol. Twenty-five mongrel dogs
(22 ± 3.2 kg) were anesthetized with sodium pentobarbital ,
0735-1097/86/$3 .50
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Eso and Ew = energy levels required for 50 and 90% success of
defibrillation, respectively (values in joules). NS = not significant.
Table 1. MeanEso and E90 Values Before and After Treatment
in 12 Control Dogs
Mean ± SD 5.04 ± 2.07 5.21 ± 2.73 6.97 ±2.82 7.34 ± 3.54
I P = NS I I P = NS I
Results
Defibrillation curves. For all dogs, both before and after
lidocaine infusion, a range of energy levels associated with
an increasing probability of successful defibrillation was
found, with a mean ratio of 2.04 ± 0.53 between energy
levels associated with an 80 to 100% and a 0 to 20% like-
lihood of success, respectively. The probability of success
at any given energy level during the entire experiment for
control dogs and during either the baseline or the postin-
fusion period for lidocaine-treated dogs, when analyzed by
After
Saline
Ew (J)
Before
Saline
After
Saline
Eso (1)
Before
Saline
of the second set of shocks. Ventricular refractory periods
were measured at a constant drive cycle length using stan-
dard methods, before and after each defibrillation curve
determination.
Single energy defibrillation. In a second set of exper-
iments (11 = 5), a single energy level with 80 to 100%
successful defibrillation was established in 5 to 10 trials.
Sequences of five trials at this energy level were repeated
30 and 60 minutes after the start of lidocaine infusion, and
45 minutesafter discontinuation of the drug. Lidocaineplasma
concentrations were measured after 30 and 60 minutes of
infusion and 45 minutes after stopping the drug, using an
enzyme-linked immunoassay (EMIT, Syva Corp.). Because
only slight positive correlations between the estimated en-
ergy required for 50% success and body weight (r = 0.65)
and heart weight (r = 0.66) (p < 0.06, NS) were observed,
results are expressed in joules, not corrected for weight.
Statistical analysis. The relation between energy and
percent of successful defibrillations for each dog was fit to
a sigmoidal "dose-response" curve using logistic regression
techniques. The energy levels associated with predicted 50
and 90% success (Eso and Ego, respectively) were calculated,
and comparison between pretreatment and posttreatment pe-
riods was made using paired t tests, and between saline-
treated and lidocaine-treated dogs using unpaired t tests.
Systematic variations in the likelihood of success at a given
energy level over time were assessed with multiple logistic
regression. The relation between lidocaine concentration
and change in defibrillation energy requirement (Eso) was
analyzed by linear regression. A probability (p) value less
than 0.05 was considered statistically significant for all
analyses.
25 mg/kg body weight, intravenously followed by 2 to 3
mg/kg per h as necessary; they were maintained on humid-
ified room air with a Harvard model 613 respirator, with
adjustments based on hourly measurements of arterial blood
gases. Normal saline solution was infused at 2 cc/kg per h
throughout the experiment, and normothermia was main-
tained with a heating blanket. Through a left thoracotomy,
the heart was exposed and suspended in a pericardial cradle.
A 13.5 crrr' titanium mesh patch identical to that used in pa-
tients in conjunction with the AICD automatic implantable
defibrillator (Intec Systems, Inc.) was sutured to the an-
terolateral left ventricle; a titanium spring lead with about
10 cnf surface area was inserted into the right atrium through
the atrial appendage and secured with a suture. A bipolar
platinum-iridium electrode embedded in an acrylic button
was sutured to the right ventricular epicardium. Drug (or
saline solution) was infused into a femoral vein through a
Harvard model 941 syringe pump. Surface electrocardio-
graphic leads II and aVL and femoral artery blood pressure
were continuously monitored on a Beckman model E108
oscilloscope and recorded on a paper recorder (Honeywell
model 941 Visicorder) at 2.5 to 250 mm/s.
Ventricular fibrillation was induced with 60 Hz fully
rectified current through the right ventricular electrodes;
after 15 seconds of fibrillation, defibrillation shocks were
applied across the ventricular patch and right atrial spring
electrodes, with the patch acting as the cathode. The wave-
form used was a truncated exponential with 60% tilt, and
the initial voltage was varied to deliver a 7 ms pulse into a
50 n load for all energies. The pulses were delivered by a
battery-operated device with energy variable from 1 to 40
J. Pulse waveforms were recorded on a Tektronix model
7623A storage oscilloscope, and initial and final current and
pulse duration were recorded.
Defibrillation curve measurements. Fibrillation-defi-
brillation trials were carried out every 3 minutes as follows:
six energy levels in 1 to 2 J increments were chosen, which
were expected to span the range from uniform failure to
uniform success in defibrillation. Six shocks (one at each
energy level) were then applied in random order, and a
similar series of six randomly ordered shocks was repeated
five times to establish a baseline energy versus percent suc-
cess curve. Saline solution (11 = 12) (control dogs) or lid-
ocaine (11 = 8), in a 3 or 5 mg/kg loading infusion over
10 minutes followed by 50 or 100 ltg/kg per min mainte-
nance infusion, was then administered. After 80 minutes,
a second set of defibrillatory shocks, at four energy levels
chosen to fall in the middle of the percent success versus
energy curve, were applied to determine a second defibril-
lation curve. If any first attempt at defibrillation was un-
successful, a 16 to 20 J rescue shock was applied within
10 seconds; only the initial shocks were used for analysis.
Arterial blood was drawn for lidocaine plasma concentration
analysis just before and at 30 and 60 minutes after the start
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oFigure 1. Relation between percent successful
defibrillation and energy before (closed circles)
and after (open circles) lidocaine administration
in order of increasing steady state plasma con-
centration (upper left corner, J-Lg/ml).
multiple logistic regression, did not vary significantly with
time. Similarly, among the 12 control animals, the percent
success-energy curve was not significantly affected by saline
infusion (Table 1) and the energy levels associated with 50
(Eso) and 90% (E90 ) success remained relatively constant.
The relation between delivered current and percent success
was qualitatively similar to that for energy. The relation
between current and success cannot be shown graphically
because each shock is associated with a unique current value.
The relation between the energy level and the likelihood
of successful defibrillation in the first set of experiments is
shown in Figure J. At baseline, the lidocaine-treated group
had a success-energy relation similar to that of the control
animals; mean Eso and E90 values were not significantly
different between control and treated dogs at baseline (Ta-
bles 1 and 2). After administration of lidocaine, there was
a marked decrease in the percent of successful defibrillations
for most energy levels, expressed as a rightward shift in the
percent success versus energy curve (Fig. 1). The mean Eso
was increased after lidocaine administration by 61.1 ± 34%,
from 5.3 ± 1.4 to 8.7 ± 3.2 J (p < 0.005), and the mean
E90 was increased by 47.1 ± 28.6%, from 7.5 ± 1.7 to
11.3 ± 4.0 J (p < 0.005). Figure 2 shows the baseline and
postdrug fitted curves for a representative dog; in this dog
only 40% of shocks were successful in defibrillation at the
highest energy levels, which had been uniformly (100%)
successful before lidocaine administration.
Lidocaine concentration-response relation. Figure 3
shows the relation between log steady-state lidocaine con-
centrations and changes in energy levels associated with
50% success rate (Eso) . There is a linear increase in defi-
brillation energy requirement with increasing drug concen-
trations, with a significant positive correlation between log
lidocaine concentration and proportional increase in Eso
(r = 0.887, P < 0.01). Similarly, in each animal the energy
level associated with an estimated 90% success rate before
lidocaine administrationhad only an estimated 32.0 ± 32.0%
success rate after drug administration, with a positive cor-
relation between log lidocaine concentration and the fall in
success rate (r = 0.812, P < 0.01).
Table 2, Eso and ~ Values Before and After Lidocaine Treatment in Eight Study Dogs
Eso E90 Lidocaine
Case Pre Post d% Pre Post d% Concentration
I 4.31 5.55 +28.8 7.47 9.21 +23.3 3.9
2 7.40 12.69 +71.5 9.09 17.39 +91.3 6.7
3 5.45 5.78 + 6.1 7.04 7.68 + 9.1 1.95
4 6.63 10.98 +65.6 8.86 14.70 +65.9 8.0
5 2.89 4.02 +39.1 3.88 5.26 +35.6 3.05
6 6.25 11.47 +83.5 8.57 14.13 +64.9 4.7
7 4.53 9.54 + 110.6 6.99 11.53 +64.9 9.8
8 5.29 9.72 +83.7 8.37 10.16 +21.4 6.7
Mean 5.34 8.72 +61.1 7.53 11.26 +47.1 5.6
±SD ± 1.44 ±3.18 ±34.1 ± 1.68 ±4.0 ±28.6 ±2.65
I P < 0.0051 I P < 0.0051
All values are in joules. Lidocaine concentration = steady state lidocaine concentration in /Lg/ml. Post =
value after lidocaine administration: Pre = baseline value before lidocaine administration; d% =
value after lidocaine
------ - I. Other abbreviations as in Table I.
baseline value
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Figure 3. Linear regression analysis of the relation betweensteady
state (55) lidocaine concentration and percent increase in the en-
ergy required for 50% success (E50) after lidocaine infusion,
Figure 2. Percent successful defibrillation (DF) versus energy
curves fitted by logistic regression analysis and raw data points
before (solid curve, closed circles) and after (dashed curve, open
circles) lidocaine administration in a representative dog. C =
lidocaine concentration (ug/rnl) steady state; E50 and ~o =P the
estimated energies required for 50 and 90% success, respectively,
and ventricular refractoriness were not altered by lidocaine .
Howe ver, to produce ventricular fibrillation , the fibrillating
pulse had to be applied for con siderably longer periods after
lidocaine treatment , suggesting that the threshold for fi-
brillation was , as expected , elevated in our experiment.
Figure 4. Demonstration of reversibility of the lidocaine effect
on defibrillation (DF)energy requirements. *p < 0.01; tp < 0.05 .
Discussion
Experimental effects oflidocaine in defibrillation. The
most commonly measured determinant of the energy re-
quirement for defibrillation is the "defibrillation threshold "
(3,15- 17). A single " threshold" value for energy (or cur-
rent) is identified, usually by gradually increasing levels of
shock energy until successful defibrillation occurs, or by
progressively decreasing energy levels until a shock fails to
defibrillate. Using such methods in pentobarbital-anesthe-
tized dogs, Babbs et al. (13) found a maximal increase of
48% in the defibrillation energy "threshold" for transthor-
acic shocks after a 3 mg/kg intravenous bolus of lidocaine ,
and an increa se of 99% after an 80 minute infusion of 0.5
mg/kg per minute. Lidocaine plasma concentrations were
not measured in that stud y; Kerber et al. (18) found a 60%
increase in transthoracic "defibrillation threshold " at 2 hours
after a loading and maintenance infusion of lidocaine in
pentobarbital-anesthetized dogs , which occurred at mean
concentrations of both 6 .2 and 15,0 jLg/ml.
Measurement of defibrillation energy requirements.
As we have previously reported (14) and as illustrated in
Figures I and 2, the distinction between inadequate and
sufficient energy for defibrillation is not a sharp one , and a
relatively wide range of energy levels with intermediate
probabilities of success can be identified. After infusion of
lidocaine, the percent success-energy was shifted rightward
in all dogs, and four of eight had 40% or fewer successes
at energy levels that were 100% successful before treatment,
The high correlation between lidocaine plasma concentra-
y =129.08 log. - 28 .94
r =0 .887; p<O.Ol
•
•
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Single energy defibrillation. To establish whether the
effect of lidocaine was reversible , five animals were studied
at a single energy level before , during and after lidocaine
administration, Figure 4 shows the mean percent success in
defibrillation during this experiment and the corresponding
lidocaine concentrations , The mean percent success de-
creased from 90 ± 10% at baseline to 76 ± 26% at 30
minutes (p = NS) and to 43 ± 23% at 60 minutes (p <
0.01) . The mean plasma lidocaine concentrations at 30
(7.3 ± 1.3 jLg/ml) and 60 minutes (8.4 ± 2.1 jLg/ml ) were
not significantly different. After drug washout, 45 minutes
after the infusion was discontinued, the mean proportion of
successful defibrillations had risen to 92 ± 18% (p < 0,05)
at a time when mean plasma lidocaine concentration had
declined to 1.8 ± 0,5 jLg/ml. Heart rate , blood pressure
JACC Vol. 8, No.2
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tion and the extent of increase in Eso supports a direct role
for lidocaine in increasing defibrillation energy require-
ments. Although the choice of the energy levels associated
with 50% success (Eso) or 90% success (E90) as measures
of energy requirement for defibrillation are arbitrary, the
logistic curve fit allows the calculation of the estimated
probability of success at any energy level (Fig. 3). The
construction of such curves allows a more precise analysis
of the effects of interventions on the electrical "dose" for
defibrillation.
The results for animals studied at a single energy level
(Fig. 4) demonstrate that the lidocaine-induced increase in
energy requirements for defibrillation are fully reversible,
and that the residual small concentrations (1.8 ± 0.5p,g/ml)
of lidocaine seem to have no effect. The maximal fall in
success rate was observed at 60 minutes after the start of
drug infusion; four of five animals showed a progressive
decrease in percent success from 30 to 60 minutes after drug
administration, during a time when plasma concentrations
were stable. The fact that multiple logistic regression anal-
ysis showed no significant change in the results over time
during the postlidocaine curve determinations in the first set
of experiments suggests that the maximal effect may be
achieved within 80 minutes after drug administration. Other
reports also note an apparent delay in maximal drug effect
(13,18). Because the antiarrhythmic effect of lidocaine has
a rapid onset after administration (8,9,19), and because
lidocaine shows rapid distribution kinetics (20), this delay
in maximal effect suggests a discrepancy between the an-
tiarrhythmic actions of lidocaine and its influence on defi-
brillation energy requirements.
Lidocaine and external defibrillation. The limited in-
formation available in humans does not confirm a clinically
important effect of lidocaine on defibrillation in the setting
of cardiac arrest. In a prospective observational study, Ker-
ber et al. (21) found no difference in the rate of successful
defibrillation between patients receiving lidocaine before
their arrhythmia and those not receiving the drug; Babbs et
al. (22) found no effect of lidocaine on defibrillation in
patients undergoing cardiac surgery. The effect of lidocaine
in patients with ventricular fibrillation resistant to defibril-
lation has not been well studied. In a nonrandomized com-
parison of lidocaine treatment with no antiarrhythmic treat-
ment for patients with ventricular fibrillation refractory to
countershock (23), no significant differences were found,
with a low proportion of patients (21 and 17%, respectively)
admitted to the coronary care unit. Whether lidocaine is
therapeutic or potentially harmful in this setting is not known.
It is, however, no more effective than bretylium in estab-
lished cardiac arrest (24), and its routine use in the preven-
tion of ventricular fibrillation has been questioned (25).
Effect of antiarrhythmic drugs on internal defibril-
lation. Quinidine, at concentrations usually achieved in
clinical use, has no effect on defibrillation energy require-
ments for internal defibrillation (26); similarly, procain-
amide and digoxin have no effect (27). Although bretylium
was reported to decrease energy requirements for transthor-
acic shocks (28), it likewise was without significant effect
in dogs tested with an internal electrode system (26).
Encainide and its metabolite ODE (o-demethyl encain-
ide), but not its MODE (3-methoxy-o-demethyl encainide)
metabolite, lead to large increases in energy requirements,
consistent with the drug-toxic arrhythmias resistant to de-
fibrillation occasionally seen after encainide therapy (29).
Amiodarone, given intravenously to dogs with implanted
electrodes, leads to a decrease in defibrillation energy, and
long-term oral amiodarone has no effect (30), although lim-
ited clinical information (31) suggests that arniodarone-treated
patients may require higher energy levels than those not
taking the drug.
Limitations of the study. Our study has several limi-
tations. The relation between the occurrence of a ventricular
fibrillation and defibrillation in anesthetized healthy dogs
and its occurrence in patients with cardiac disease is not
known; however, the "defibrillation threshold" is not sig-
nificantly different in awake and pentobarbital-anesthetized
dogs (32). Because the energy requirements are so much
smaller for intracardiac defibrillation than for transthoracic
shocks, the large relative changes after lidocaine adminis-
tration observed in this study cannot be directly extrapolated
to energy requirements for external defibrillation. However,
they suggest that the use of lidocaine and lidocaine-like
drugs should be reassessed in patients in whom internal or
external defibrillation is difficult.
Conclusion. Lidocaine causes a reversible, concentra-
tion-dependent increase in the energy requirements for suc-
cessful defibrillation; recommendations to administer lido-
caine in the setting of ventricular fibrillation resistant to
defibrillation may need to be reviewed.
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